Aclaris Therapeutics, Inc. (ACRS)

Current Report Filed: 2026-04-28

Key Insights

• Aclaris announced positive Phase 1a results for ATI-052, a bispecific antibody targeting anti-TSLP/IL-4Rα, demonstrating clinical progress in its pipeline and de-risking early-stage development.
• The company selected lichen planus as the lead indication for ATI-2138 (selective ITK/JAK3 inhibitor), indicating advancement in clinical development strategy and potential market opportunity identification for this asset.
• This is a Regulation FD disclosure filed via 8-K, meaning the information is being disclosed to the market through a conference call presentation and press release, which is typical for clinical trial results from biotech companies.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-04-27

Key Insights

• Director Leonard Braden Michael sold 300,000 shares on 04/23/2026 at $4.53 per share, generating approximately $1.36 million in proceeds, indicating a substantial insider sale transaction.
• Following the sale, Michael maintains indirect beneficial ownership of 13,950,000 shares through BML Investment Partners, L.P., representing a significant continued stake in the company despite the recent disposition.
• The sale occurred through a fund structure (BML Investment Partners, L.P.) where Michael exercises investment and voting control, though he disclaims beneficial ownership except for his pecuniary interest, suggesting a structured investment arrangement.
• The transaction was reported on 04/27/2026 but executed on 04/23/2026, with no indication this was pursuant to a Rule 10b5-1 trading plan, which could signal discretionary selling rather than pre-planned divestment.

Sentiment: Negative Significance: 6/10

View Original Filing →

Current Report Filed: 2026-03-11

Key Insights

• The company raised $20 million through a public stock offering, indicating potential for growth and expansion.
• The shares were purchased by several major institutional investors, suggesting strong investor confidence in the company's prospects.
• The filing does not provide any additional details about the company's financial performance or strategic plans, limiting the insight that can be gleaned from this 8-K.

Sentiment: Positive Significance: 5/10

View Original Filing →

Current Report Filed: 2026-03-10

Key Insights

• Aclaris Therapeutics raised $39.8 million through a stock offering, which could provide additional funding to support its ongoing operations and development programs.
• The shares were purchased by institutional investors, including Deep Track Capital, indicating institutional investor interest in the company.
• The filing discloses the details of the stock offering, providing transparency to investors about the company's capital-raising activities.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• The reporting person, Kevin Balthaser, was granted 99,100 restricted stock units and 346,800 stock options, vesting over 4 years, indicating a long-term commitment to the company.
• The stock options have an exercise price of $3.61, which is lower than the current market price, suggesting the reporting person believes the stock is undervalued.
• The substantial equity grants to the Chief Financial Officer signal the company's confidence in the leadership and their desire to incentivize long-term performance.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• The reporting person, James Loerop, has been granted 97,700 restricted stock units and 341,900 stock options by Aclaris Therapeutics, Inc. This indicates the company is providing equity incentives to its Chief Business Officer to align his interests with shareholders.
• The equity awards vest over 4 years, suggesting the company is focused on long-term retention and performance of its senior leadership team.
• The exercise price of the stock options is $3.61, which appears to be at the current market price, indicating the options are intended to be performance-based rather than immediately valuable.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• Insider Jesse Wayne Hall, who serves as the Chief Medical Officer, has acquired 98,100 restricted stock units and 343,300 stock options as part of his compensation package.
• The restricted stock units vest over 4 years, indicating the company's commitment to retaining Hall and aligning his interests with shareholders.
• The stock options have an exercise price of $3.61 and expire in 10 years, providing Hall with long-term incentives to drive the company's success.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• Roland Kolbeck, the Chief Scientific Officer of Aclaris Therapeutics, has been awarded 95,700 restricted stock units and granted 334,900 stock options, indicating the company's commitment to retaining and incentivizing its key executive.
• The vesting of the restricted stock units and stock options is tied to the Reporting Person's continued service with the company, aligning his interests with those of Aclaris Therapeutics' shareholders.
• The grant of these equity-based awards suggests that the company is focused on long-term value creation and is rewarding its senior leadership for their contributions to the business.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• Insider Hugh M. Davis, President and COO, acquired a substantial number of 96,100 restricted stock units and 336,300 stock options, indicating his confidence in the company's long-term prospects.
• The vesting schedule of the restricted stock units and stock options is spread over four years, suggesting a long-term alignment between Davis and the company's shareholders.
• The exercise price of the stock options at $3.61 is below the current market price, potentially providing Davis with an opportunity to benefit from future stock appreciation.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-06

Key Insights

• The CEO of Aclaris Therapeutics, Inc. (ACRS) has been granted a substantial number of restricted stock units (274,800) and stock options (961,700) with vesting over 4 years, indicating significant long-term alignment between the CEO and shareholder interests.
• The CEO's stock-based compensation suggests the company is focused on incentivizing and retaining key leadership to drive the company's long-term growth and success.
• Investors should monitor the CEO's future trading activity, as insider buying or selling patterns can provide insights into management's outlook on the company's prospects.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-05

Key Insights

• The reporting person, Kevin Balthaser, exercised 22,025 restricted stock units and sold 6,449 shares to cover tax withholding obligations, indicating ongoing vesting and ownership of the company's equity by a key executive.
• The restricted stock units vest over four years, suggesting a long-term incentive and alignment of the executive's interests with shareholders.
• The transaction represents a relatively small portion of the reporting person's total beneficial ownership, which remains at 185,755 shares after the sale.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-02-05

Key Insights

• The reporting person, Hugh M. Davis, who is the President and COO of Aclaris Therapeutics, Inc., acquired 18,675 shares of the company's common stock through the vesting of restricted stock units.
• The vested shares represent a significant portion of the reporting person's beneficial ownership, indicating their ongoing commitment to the company.
• The timing of the transaction, occurring on February 3, 2026, suggests the reporting person's confidence in the company's long-term prospects.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-05

Key Insights

• The CEO, Neal Walker, has exercised 63,475 restricted stock units and sold 18,611 shares to cover tax withholding obligations, indicating continued insider ownership and confidence in the company.
• The vesting schedule for the remaining 190,425 restricted stock units held by the CEO suggests a long-term incentive alignment with shareholders.
• The stock transaction appears to be routine and in line with the CEO's historical trading patterns, suggesting no major changes in the company's outlook or the insider's view.

Sentiment: Positive Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-02-05

Key Insights

• The reporting person, James Loerop, is the Chief Business Officer of Aclaris Therapeutics, Inc. and has exercised 20,875 restricted stock units, increasing his direct ownership to 192,260 shares.
• The reporting person also had 5,937 shares withheld by the issuer to satisfy tax withholding obligations related to the vesting of the restricted stock units.
• The restricted stock units that vested have a four-year vesting schedule, with the shares vesting in equal installments on the first, second, third, and fourth anniversaries of February 3, 2025.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-01-12

Key Insights

• Aclaris Therapeutics has updated its corporate overview presentation, which could provide investors with new information on the company's business and strategic initiatives.
• The filing does not indicate any material changes to Aclaris's financial condition, operations, or leadership, suggesting this update is likely a routine disclosure.
• Investors should review the updated presentation on the company's website for any potential insights into Aclaris's pipeline, market opportunities, or other key developments.

Sentiment: Neutral Significance: 3/10

View Original Filing →